
Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy/Economic_IndiaTimes
Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy
In the intricate realm of biotech, Eyestem Research stands at the forefront, navigating a challenging path towards regulatory approval. The recently submitted Investigational New Drug (IND) application to the Central Drugs Standards Control Organization, India (CDSCO) marks a pivotal moment for Eyestem’s therapy, Eyecyte-RPE. This groundbreaking treatment aims to address medium- and late-stage geographic atrophy, secondary to dry AMD, providing hope for patients.
Global Regulatory Landscape: A Balancing Act
Jogin Desai, CEO of Eyestem Research, sheds light on the complex dance with global regulatory agencies. Harmonization efforts are underway, with common technical documents acting as beacons across India, Australia, and Singapore. Desai emphasizes the importance of understanding each country’s unique regulatory nuances, be it India’s stringent input controls or Australia’s reliance on output controls.
The Rigorous Path to Clinical Stage: From Idea to Approval
Desai unravels the intricate lifecycle of a biotech company, detailing the rigorous journey from ideation to clinical-stage readiness. Animal trials, proof of concept, efficacy studies, and toxicity assessments constitute the arduous path. IND approval signifies a company’s maturity, signaling to investors and paving the way for impactful biotech solutions.
As Eyestem aims for IND approval, its CEO envisions a future where the company addresses not only dry AMD but also Parkinson’s and retinitis pigmentosa. With a commitment to affordability, Eyestem strives to revolutionize the cost paradigm in cell and gene therapies, offering a beacon of hope for patients globally.
In collaboration with renowned institutions like AIIMS in Delhi and LV Prasad Eye Institute, Eyestem Research propels regenerative therapies forward, setting new standards in ophthalmology. Beyond its immediate impact, this partnership hints at the transformative role Eyestem may play in the evolution of personalized and regenerative medicine.
Latest Posts
- Comptroller and Auditor General of India Flags 14.82 Lakh Incomplete MGNREGA Works in Jammu Kashmir, Rs 1,897 Crore Already Spent
October 6, 2026 | Breaking News, Jammu Kashmir, Politics - J&K Authorities Deport 150 Bangladeshi Nationals Over Alleged Illegal Stay; Another Batch Expected In October 2026
October 6, 2026 | Breaking News, India, Jammu Kashmir - J&K High Court Invites Eligible Srinagar Wing Employees to Switch From NPS to Old Pension Scheme
October 6, 2026 | Breaking News, Courts & Law, Jammu Kashmir - Leh Designated as Place for High Court Sittings in Ladakh
October 5, 2026 | Breaking News, Courts & Law, Jammu Kashmir - Army Personnel Among 8 Held in Madras Regiment Arms Heist; Telangana Police Recover Weapons
October 5, 2026 | Breaking News, India, Politics - DMK To File Rs 1 Crore Defamation Case Against Tamilaga Vettri Kazhagam Over R Veeramani Claims
October 5, 2026 | Breaking News, India, Politics - Jammu and Kashmir Cricket Association Names 18 Players for Ranji Trophy 2026-27 Preparatory Camp in Srinagar
October 5, 2026 | Breaking News, Sports - Yemen Launches Dawn of Yemen Operation Aimed at Retaking Capital Sanaa From Houthis
October 5, 2026 | Breaking News, World - Punjab and Haryana High Court Orders CBI Probe Into Corruption Allegations Linked to OSD of CM Bhagwant Mann
October 5, 2026 | Breaking News, Courts & Law, India, Politics - Yemen Government Forces Claim Control of Bab al-Mandeb Strait, Recapture Dhubab Airport
October 5, 2026 | Breaking News, World